IL-23 and TGF-β1 levels as potential predictive biomarkers in treatment of bipolar i disorder with acute manic episode

Journal of Affective Disorders

Volumn 174, Issue , 2015, Pages 361-366

  Li, Haozhe ^a   Hong, Wu ^a   Zhang, Chen ^a   Wu, Zhiguo ^a   Wang, Zuowei ^a,b   Yuan, Chenmei ^a   Li, Zezhi ^a,c   Huang, Jia ^a   Lin, Zhiguang ^a   Fang, Yiru ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Hongkou District Mental Health Center of Shanghai   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bipolar disorder; Interleukin; Mania; Transforming growth factor beta; Tumor necrosis factor alpha

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 23; LITHIUM; QUETIAPINE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; DIBENZOTHIAZEPINE DERIVATIVE; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; BIPOLAR I DISORDER; BLOOD SAMPLING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMORAL IMMUNITY; MALE; SAMPLE SIZE; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919913321     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.12.033     Document Type: Article

References (57)

1. J.G. Abreu, N.I. Ketpura, B. Reversade, and E.M. De Robertis Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta Nat. Cell Biol. 4 2002 599 604
2. S. Agrawal, S. Gollapudi, S. Gupta, and A. Agrawal Dendritic cells from the elderly display an intrinsic defect in the production of IL-10 in response to lithium chloride Exp. Gerontol. 48 2013 1285 1292
3. S. Aradhya, and D.L. Nelson NF-κB signaling and human disease Curr. Opin. Genet. Dev. 11 2001 300 306
4. M. Austin, and Y.C. Tan Mania associated with infliximab Aust. N. Z. J. Psychiatry 46 2012 684 685
5. E.A. Bachen, M.A. Chesney, and L.A. Criswell Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus Arthr. Rheum. 61 2009 822 829
6. R.Y. Bai, C. Koester, T. Ouyang, S.A. Hahn, M. Hammerschmidt, C. Peschel, and J. Duyster SMIF, a Smad4-interacting protein that functions as a co-activator in TGFbeta signalling Nat. Cell Biol. 4 2002 181 190
7. I.G. Barbosa, R.B. Huguet, V.A. Mendonca, L.P. Sousa, F.S. Neves, M.E. Bauer, and A.L. Teixeira Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder Eur. Arch.Psychiatry Clin. Neurosci. 261 2011 139 143
8. I.G. Barbosa, R. Machado-Vieira, J.C. Soares, and A.L. Teixeira The immunology of bipolar disorder Neuroimmunomodulation 21 2014 117 122
9. I.G. Barbosa, N.P. Rocha, A.S. de Miranda, P.V. Magalhaes, R.B. Huguet, L.P. de Souza, F. Kapczinski, and A.L Teixeira Increased levels of adipokines in bipolar disorder J. Psychiatr. Res. 46 2012 389 393
10. M. Berk, O. Dean, H. Drexhage, J.J. McNeil, S. Moylan, A. ONeil, C.G. Davey, L. Sanna, and M. Maes Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness BMC Med. 11 2013 74
11. J. Berwaerts, R. Lane, I.F. Nuamah, P. Lim, B. Remmerie, and D.W. Hough Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study J. Affect. Disord. 129 2011 252 260
12. J.L. Beyer An evidence-based medicine strategy for achieving remission in bipolar disorder J. Clin. Psychiatry 69 3 2008 S31 S37 (Suppl)
13. Y.B. Bezchlibnyk, J.F. Wang, G.M. McQueen, and L.T. Young Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex J. Neurochem. 79 2001 826 834
14. E. Brietzke, R. Stabellini, R. Grassi-Oliveira, and B. Lafer Cytokines in bipolar disorder: recent findings, deleterious effects but promise for future therapeutics CNS spectr. 16 2011 157 168
15. K.N. Chengappa, R.W. Baker, L. Shao, L.N. Yatham, M. Tohen, S. Gershon, and D.J. Kupfer Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania Bipolar Disord. 5 2003 1 5
16. B. Dean, A.S. Gibbons, N. Tawadros, L. Brooks, I.P. Everall, and E. Scarr Different changes in cortical tumor necrosis factor-alpha-related pathways in schizophrenia and mood disorders Mol. Psychiatry 18 2013 767 773
17. C.H. do Prado, L.B. Rizzo, A. Wieck, R.P. Lopes, A.L. Teixeira, R. Grassi-Oliveira, and M.E. Bauer Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and activated MAPK in type 1 bipolar disorder Psychoneuroendocrinology 38 2013 667 676
18. W.W. Eaton, M.G. Pedersen, P.R. Nielsen, and P.B. Mortensen Autoimmune diseases, bipolar disorder, and non-affective psychosis Bipolar Disord. 12 2010 638 646
19. L.J. Edwards, and C.S. Constantinescu A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic Mult. Scler. 10 2004 575 581
20. B. Elisa, and L. Beny Induction of manic switch by the tumour necrosis factor-alpha antagonist infliximab Psychiatry Clin. Neurosci. 64 2010 442 443
21. H. Eyre, and B.T. Baune Neuroplastic changes in depression: a role for the immune system Psychoneuroendocrinology 37 2012 1397 1416
22. K. Gee, C. Guzzo, N.F. Che Mat, W. Ma, and A. Kumar The IL-12 family of cytokines in infection, inflammation and autoimmune disorders Inflamm. Allergy Drug Targets 8 2009 40 52
23. B. Gran, G.X. Zhang, and A. Rostami Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination Crit. Rev. Immunol. 24 2004 111 128
24. M.H. Hillegers, C.G. Reichart, M. Wals, F.C. Verhulst, J. Ormel, W.A. Nolen, and H.A. Drexhage Signs of a higher prevalence of autoimmune thyroiditis in female offspring of bipolar parents Eur. Neuropsychopharmacol.: J Eur. Coll. Neuropsychopharmacol. 17 2007 394 399
25. H. Himmerich, S. Bartsch, H. Hamer, R. Mergl, J. Schonherr, C. Petersein, A. Munzer, K.C. Kirkby, K. Bauer, and U. Sack Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro J. Psychiatr. Res. 47 2013 1751 1759
26. K.A. Jones, and C. Thomsen The role of the innate immune system in psychiatric disorders Mol. Cell. Neurosci. 53 2013 52 62
27. R.A. Khairova, R. Machado-Vieira, J. Du, and H.K. Manji A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder Int. J. Neuropsychopharmacol./Off. Sci. J. Coll. Int. Neuropsychopharmacol. 12 2009 561 578
28. Y.K. Kim, H.G. Jung, A.M. Myint, H. Kim, and S.H. Park Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder J. Affect. Disord. 104 2007 91 95
29. Y.K. Kim, A.M. Myint, B.H. Lee, C.S. Han, S.W. Lee, B.E. Leonard, and H.W. Steinbusch T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients Psychiatry Res. 129 2004 267 272
30. E.M. Knijff, M.N. Breunis, R.W. Kupka, H.J. de Wit, C. Ruwhof, G.W. Akkerhuis, W.A. Nolen, and H.A Drexhage An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment Bipolar Disord. 9 2007 743 753
31. M.A. Kroenke, T.J. Carlson, A.V. Andjelkovic, and B.M. Segal IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition J. Exp. Med. 205 2008 1535 1541
32. R.W. Kupka, W.A. Nolen, R.M. Post, S.L. McElroy, L.L. Altshuler, K.D. Denicoff, M.A. Frye, P.E. Keck Jr.; G.S. Leverich, A.J. Rush, T. Suppes, C. Pollio, and H.A. Drexhage High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure Biol. Psychiatry 51 2002 305 311
33. Y. Liu, J.T. Yu, W. Zhang, Y. Zong, R.C. Lu, J. Zhou, and L. Tan Interleukin-23 receptor polymorphisms are associated with Alzheimers disease in Han Chinese J. Neuroimmunol. 271 2014 43 48
34. F. Magro, and F. Portela Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies BioDrugs: Clin. Immunother. Biopharm. Gene Ther. 24 1 2010 S3 S14 (Suppl)
35. P.R. Mangan, L.E. Harrington, D.B. OQuinn, W.S. Helms, D.C. Bullard, C.O. Elson, R.D. Hatton, S.M. Wahl, T.R. Schoeb, and C.T. Weaver Transforming growth factor-beta induces development of the T(H)17 lineage Nature 441 2006 231 234
36. M.J. McGeachy, and D.J. Cua The link between IL-23 and Th17 cell-mediated immune pathologies Semin. Immunol. 19 2007 372 376
37. A. Modabbernia, S. Taslimi, E. Brietzke, and M. Ashrafi Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies Biol. Psychiatry 74 2013 15 25
38. K. Munkholm, J.V. Brauner, L.V. Kessing, and M. Vinberg Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis J. Psychiatr. Res. 47 2013 1119 1133
39. F.G. Nery, E.S. Monkul, J.P. Hatch, M. Fonseca, G.B. Zunta-Soares, B.N. Frey, C.L. Bowden, and J.C. Soares Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study Hum. Psychopharmacol. 23 2008 87 94
40. A.M. Nivoli, F. Colom, A. Murru, I. Pacchiarotti, P. Castro-Loli, A. Gonzalez-Pinto, K.N. Fountoulakis, and E. Vieta New treatment guidelines for acute bipolar depression: a systematic review J. Affect. Disord. 129 2011 14 26
41. A.M. Nivoli, A. Murru, J.M. Goikolea, J.M. Crespo, J.M. Montes, A. Gonzalez-Pinto, P. Garcia-Portilla, J. Bobes, J. Saiz-Ruiz, and E. Vieta New treatment guidelines for acute bipolar mania: a critical review J. Affect. Disord. 140 2012 125 141
42. S.M. OBrien, P. Scully, L.V. Scott, and T.G. Dinan Cytokine profiles in bipolar affective disorder: focus on acutely ill patients J. Affect. Disord. 90 2006 263 267
43. K. Ohkusu-Tsukada, N. Tominaga, H. Udono, and K. Yui Regulation of the maintenance of peripheral T-cell anergy by Table1-mediated p38 alpha activation Mol. Cell. Biol. 24 2004 6957 6966
44. B. Oppmann, R. Lesley, B. Blom, J.C. Timans, Y. Xu, B. Hunte, F. Vega, N. Yu, J. Wang, K. Singh, F. Zonin, E. Vaisberg, T. Churakova, M. Liu, D. Gorman, J. Wagner, S. Zurawski, Y. Liu, J.S. Abrams, K.W. Moore, D. Rennick, R. de Waal-Malefyt, C. Hannum, J.F. Bazan, and R.A Kastelein Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 Immunity 13 2000 715 725
45. M. Pompili, Z. Rihmer, M. Innamorati, D. Lester, P. Girardi, and R. Tatarelli Assessment and treatment of suicide risk in bipolar disorders Expert Rev. Neurother. 9 2009 109 136
46. C.L. Raison, R.E. Rutherford, B.J. Woolwine, C. Shuo, P. Schettler, D.F. Drake, E. Haroon, and A.H. Miller A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers JAMA Psychiatry 70 2013 31 41
47. J.S. Rao, G.J. Harry, S.I. Rapoport, and H.W. Kim Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients Mol. Psychiatry 15 2010 384 392
48. J. Savitz, S. Preskorn, T.K. Teague, D. Drevets, W. Yates, and W. Drevets Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2×2 clinical trial BMJ Open 2 2012 e000643
49. Y. Shi, and J. Massague Mechanisms of TGF-beta signaling from cell membrane to the nucleus Cell 113 2003 685 700
50. J. Soderlund, S.K. Olsson, M. Samuelsson, L. Walther-Jallow, C. Johansson, S. Erhardt, M. Landen, and G. Engberg Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder J. Psychiatry Neurosci. 36 2011 114 118
51. P.P. Tak, and G.S. Firestein NF-kappaB: a key role in inflammatory diseases J. Clin. Investig. 107 2001 7 11
52. E. Toussirot The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases Inflamm. Allergy Drug Targets 11 2012 159 168
53. C. Ulusoy, E. Tuzun, M. Kurtuncu, R. Turkoglu, G. Akman-Demir, and M. Eraksoy Comparison of the cytokine profiles of patients with neuronal-antibody-associated central nervous system disorders Int. J. Neurosci. 122 2012 284 289
54. F. Verrecchia, M. Pessah, A. Atfi, and A. Mauviel Tumor necrosis factor-alpha inhibits transforming growth factor-beta /Smad signaling in human dermal fibroblasts via AP-1 activation J. Biol. Chem. 275 2000 30226 30231
55. J. Vom Berg, S. Prokop, K.R. Miller, J. Obst, R.E. Kalin, I. Lopategui-Cabezas, A. Wegner, F. Mair, C.G. Schipke, O. Peters, Y. Winter, B. Becher, and F.L. Heppner Inhibition of IL-12/IL-23 signaling reduces Alzheimers disease-like pathology and cognitive decline Nat. Med. 18 2012 1812 1819
56. L.N. Yatham, S.H. Kennedy, S.V. Parikh, A. Schaffer, S. Beaulieu, M. Alda, C. O'Donovan, G. Macqueen, R.S. McIntyre, V. Sharma, A. Ravindran, L.T. Young, R. Milev, D.J. Bond, B.N. Frey, B.I. Goldstein, B. Lafer, B. Birmaher, K. Ha, W.A. Nolen, and M. Berk Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013 Bipolar Disord. 15 2013 1 44
57. R.C. Young, J.T. Biggs, V.E. Ziegler, and D.A. Meyer A rating scale for mania: reliability, validity and sensitivity Br. J. Psychiatry 133 1978 429 435